CIBC Bancorp USA’s ImmunityBio IBRX Stock Holding History

CIBC Bancorp USA’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$275K	Buy	31,435 +6,046	+24%	+$45.8K	﹤0.01%	1581
2026 Q1	$194K	Buy	+25,389	New	+$174K	﹤0.01%	1626
2025 Q3	$60.3K	Buy	+24,521	New	+$63.1K	﹤0.01%	1403

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC Bancorp USA's IBRX Position: Q2 2026 in Review

CIBC Bancorp USA increased its ImmunityBio (IBRX) stake by 24% in Q2 2026, buying an estimated $45.8K and bringing the position to 31,435 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #1581.

CIBC Bancorp USA first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

CIBC Bancorp USA held 31,435 shares of ImmunityBio worth $275K as of Q2 2026.
CIBC Bancorp USA bought 6,046 ImmunityBio shares in Q2 2026, an estimated $45.8K.
ImmunityBio made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1581 holding.
CIBC Bancorp USA first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.